Azitra Reschedules Special Meeting to Approve Share Issuance

An announcement from Azitra Inc ( (AZTR) ) is now available.

On February 6, 2026, Azitra Inc. convened but immediately adjourned a special meeting of stockholders after determining that only about 13% of outstanding common shares were represented, well below the one‑third quorum requirement, and rescheduled the meeting to March 6, 2026, to solicit additional votes. The reconvened virtual meeting will ask shareholders to approve the potential issuance of more than 19.99% of Azitra’s outstanding common stock under a securities purchase agreement with Alumni Capital LP, as well as the option to adjourn again if needed, a vote that could be important for the company’s financing plans and capital structure; investors of record as of January 2, 2026, who have not yet voted are being urged to do so by mail, internet, telephone or during the reconvened meeting, while previously submitted proxies remain valid unless changed.

The most recent analyst rating on (AZTR) stock is a Hold with a $0.23 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.

Spark’s Take on AZTR Stock

According to Spark, TipRanks’ AI Analyst, AZTR is a Neutral.

The score is primarily held back by weak financial performance: no TTM revenue, large ongoing losses, and significant cash burn despite an improved, low-debt balance sheet. Technicals provide only modest support (short-term improvement but longer-term downtrend), while valuation is constrained by negative earnings and no dividend yield.

To see Spark’s full report on AZTR stock, click here.

More about Azitra Inc

Azitra Inc., based in Branford, Conn., is a clinical-stage biopharmaceutical company focused on precision dermatology, developing engineered microbial therapies for serious skin conditions. Its lead program, ATR-12, uses an engineered strain of S. epidermidis to treat Netherton syndrome, a rare and potentially fatal chronic skin disease with no approved therapies, and is being evaluated in a Phase 1b trial in adult patients. A second advanced program, ATR-04, targets rashes associated with EGFR inhibitors using another engineered S. epidermidis strain; the program has an open IND and has received FDA Fast Track designation for this indication, which affects an estimated 150,000 people in the U.S. The company’s pipeline is built on a proprietary platform of engineered proteins and topical live biotherapeutic products supported by a microbial library of about 1,500 bacterial strains and augmented by artificial intelligence and machine learning tools for screening and optimization.

Average Trading Volume: 864,296

Technical Sentiment Signal: Sell

Current Market Cap: $2.47M

For a thorough assessment of AZTR stock, go to TipRanks’ Stock Analysis page.